Reinovax Biologics
Latest round
- Series B
Last raised
- Jan 2026
Total raised
- $29M
Investors
- 1
About Reinovax Biologics
, trading as Reinovax Biologics, is a biotechnology company focused on the research, development, and industrialization of novel vaccines and recombinant protein-based biopharmaceuticals., Ltd. initiated pilot-scale development for its proprietary 24-valent pneumococcal conjugate vaccine (PCV24)., Ltd., Ltd. in May 2020, which oversees large-scale GMP vaccine manufacturing. By 2024, the company completed construction of its Changchun manufacturing site and entered Phase II clinical trials for PCV24 targeting adults and Phase I trials for pediatric populations. The company works with medical researchers and biopharmaceutical firms to provide innovative vaccine solutions. Core products include PCV24, a 24 valent pneumococcal conjugate vaccine designed to cover over 90 percent of pathogenic serotypes in China. The company is also developing a novel meningococcal vaccine and offers contract development and manufacturing services. The company generates revenue through R&D partnerships, contract biomanufacturing services, and anticipated future sales of proprietary vaccine products pending regulatory approval. Reinovax Biologics plans to initiate clinical trials for the adult indication of its PCV24 vaccine and advance trials for the infant indication.
Who invested in Reinovax Biologics
1 investor across 1 round
See all investors in Reinovax Biologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jan 9, 2026
Amount
$29M
Investors
Questions about Reinovax Biologics
Who invested in Reinovax Biologics?
Reinovax Biologics has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Reinovax Biologics raised?
Reinovax Biologics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Reinovax Biologics last raise money?
Reinovax Biologics's most recent round on record is a Series B, in Jan 2026.
What does Reinovax Biologics do?
, trading as Reinovax Biologics, is a biotechnology company focused on the research, development, and industrialization of novel vaccines and recombinant protein-based biopharmaceuticals.
Where is Reinovax Biologics headquartered?
Reinovax Biologics is headquartered in Shanghai, China.
Which VCs invest in companies like Reinovax Biologics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Reinovax Biologics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Reinovax Biologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.